Safety Assessment of Icotinb in Advanced NSCLC Patients With Hepatic Insufficiency: A Multi-center, Open-label, Single-arm Study
Phase of Trial: Phase II
Latest Information Update: 10 Jul 2017
Price : $35 *
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Betta Pharmaceuticals Co Ltd
- 26 Dec 2014 According to ClinicalTrial.gov record, planned End Date changed from 1 May 2015 to 1 Jun 2016.
- 26 Dec 2014 According to ClinicalTrial.gov record, planned primary completion date changed from 1 Feb 2015 to 1 Dec 2015.
- 26 Jun 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.